Teva Pharma (TEVA) Reports In-Line Q1 EPS on Light Revs

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) reported Q1 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4.25 billion.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
• Darden Restaurants stock slips premarket despite Q4 earnings beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance